Table 1.

Clinical trials of immunotherapies combinations in locally advanced unresectable and metastatic HCC

Trial identifier	Line	Agents	Primary endpoint	Patients	Status
NCT03713593	First line	Lenvatinib + pembrolizumab vs. lenvatinib	PFS, OS	750	Ongoing
NCT03764293	First Line	PD-1 antibody SHR-1210 + apatinib mesylate vs. sorafenib	PFS, OS	510	Ongoing
NCT03298451	First line	Durvalumab vs. durvalumab + tremelimumab vs. sorafenib	OS	1,310	Active, not recruiting
NCT03412773	First line	BGB-A317 (PD-1 antibody) vs. sorafenib	OS	674	Active, not recruiting
NCT03434379	First line	Atezolizumab + bevacizumab vs. sorafenib	OS, PFS	480	Active, not recruiting
NCT01658878	First line	Nivolumab + cabozantinib vs. nivolumab + ipilimumab + cabozantinib	Safety, tolerability and ORR	1,097	Active, not recruiting
NCT03347292	First line	Pembrolizumab + regorafenib	TEAEs, DLTs	57	Ongoing, recruiting
NCT03439891	First line	Nivolumab + sorafenib	MTD, ORR	40	Ongoing, recruiting

PFS, progression free survival; OS, overall survival; TTP, time to progression; TR-RECIST, tumor response using Response Evaluation Criteria in Solid Tumors (RECIST); ORR, objective response rate; TEAEs, treatment-emergent adverse events; DLTs, dose limiting toxicities; MTD, maximum tolerated dose.